Cat.No.L3800
A unique collection of 4200 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS).
Cited by 335 Publications
• A unique collection of 4200 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS)
•Drug repurposing, the application of known drugs to treat new disease indication, holds potential of rapid clinical impact at a lower cost than de novo drug development
• Safety confirmed by clinical phase 1
• Related to oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia etc
• Structurally diverse, medicinally active, and cell permeable.
• Rich documentation with structure, IC50, and customer reviews
• NMR and HPLC validated to ensure the highest purity
| Formulation | 3768 compounds pre-dissolved in 10mM DMSO, 301 compounds pre-dissolved in 10mM water, 110 compounds pre-dissolved in 2mM DMSO, 19 compounds pre-dissolved in 2mM water and 2 compounds pre-dissolved in 2mg/ml DMSO | ||
|---|---|---|---|
| Container | 96 Deep Well Plate Sealed With Aluminum Foil | ||
| Stability | 12 months | -20°C | in DMSO |
| 24 months | -80°C | in DMSO | |
| Shipping | Blue ice or dry ice | ||
Application of GPCR Compound Library in liver cancer (This article was published in Nature (IF=43) and took about 15 months):
Application of Kinase Inhibitor Library in colorectal cancer (This article was published in Nature Communications (IF=11) and took about 8 months):
Application of FDA-approved Drug Library in antivirus (This article was published in Cell Research (IF=17) and took about 13 months):
Application of FDA-approved Drug Library in metabolism (This article was published in Movement Disorders (IF=8) and took about 10 months):
Application of Epigenetics Compound Library in acute lymphoblastic leukemia (This article was published in Blood (IF=16) and took about 16 months):
Application of Inhibitor Library in tumor immunology (This article was published in Cancer Immunol Res (IF=8.6) and took about 12 months):